The invention relates to compositions, kits, and methods for cancer therapyusing recombinant MVA viruses encoding a tumor-associated antigen, such asHER-2, particularly in combination with taxanes. The taxanes can be administeredprior to, at the same time as, or after the recombinant MVA virus.